Get the latest news, insights, and market updates on BDX (Becton, Dickinson and Company). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Is BD’s (BDX) Expanded European Diagnostics Menu Quietly Reshaping Its Competitive Moat?
BD (Becton, Dickinson and Company) recently expanded its European infectious disease diagnostics portfolio after IVDR certification of two Certest Biotec VIASURE assays for the fully automated BD MAX™ System, covering a wide range of respiratory and sexually transmitted pathogens from streamlined sample workflows. This broadening of the BD MAX™ assay menu deepens BD’s role in high-throughput molecular testing, strengthening its position in hospital and clinical laboratory workflows that rely... Dec 16, 2025 - $BDX
PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors
Appointment Enhances PolyPid’s Strategic, Commercial and Transaction Capabilities Ahead of D-PLEX₁₀₀ New Drug Application SubmissionPETACH TIKVA, Israel, Dec. 16, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced the appointment of Brooke Story as Chairman of the Board of Directors, effective as of December 11, 2025. “Brooke’s appointment marks an exciting and pivotal moment for P Dec 16, 2025 - $BDX
Is Becton Dickinson Now an Opportunity After Diagnostics Expansion and 2026 Business Separation Plans?
If you have been wondering whether Becton Dickinson is quietly turning into a value opportunity or just a value trap, you are not alone. This breakdown is designed to give you a clear, no jargon view of where the stock really stands. The share price has bounced 5.6% over the last week and 3.7% over the past month, even though it is still down 11.7% year to date and 10.2% over the last year. This mix often signals shifting expectations around growth and risk. Recent headlines have focused on... Dec 16, 2025 - $BDX
BD Expands BD MAX™ System Menu with New IVDR-Certified VIASURE Assays in Partnership with Certest Biotec
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the expansion of its respiratory and sexually transmitted infection (STI) diagnostics offerings in Europe following In Vitro Diagnostic Medical Device Regulation (IVDR) certification of two VIASURE assays developed by Certest Biotec for use on the BD MAX™ System. The addition of these new assays to the BD MAX™ System portfolio enables clinical laboratories to detect a broad range of patho Dec 15, 2025 - $BDX
Becton Dickinson, Bio-Rad, and Thermo Fisher Propel Safety and Automation in Blood Collection Tubes—New Market Report Highlights $7Billion Opportunity
The blood collection tubes market presents opportunities through innovation in automated systems, advanced materials, and digital traceability to enhance workflow efficiency and compliance. Demand is driven by personalized medicine, diagnostic volume growth, and regulatory needs, with a focus on agility and regional adaptation. Blood Collection Tubes Market Blood Collection Tubes Market Dublin, Dec. 12, 2025 (GLOBE NEWSWIRE) -- The "Blood Collection Tubes Market - Global Forecast 2025-2032" has Dec 12, 2025 - $BDX
Morgan Stanley Highlights Positive Outlook for Becton, Dickinson (BDX) and the MedTech Sector
Becton, Dickinson and Company (NYSE:BDX) is included among the 15 Best Stocks to Buy for the Long Term. On December 2, Morgan Stanley analyst Patrick Wood lifted the firm’s price target on Becton, Dickinson and Company (NYSE:BDX) to $210 from $197 and maintained an Overweight rating on the shares. The analyst noted that the company’s […] Dec 11, 2025 - $BDX
Assessing Becton Dickinson’s (BDX) Valuation After a Year-to-Date Share Price Decline
Becton Dickinson (BDX) has quietly slipped this year, with the stock down about 16% year to date even as annual revenue and net income still show steady growth. This creates a potentially interesting entry point. See our latest analysis for Becton Dickinson. Over the past few months, Becton Dickinson’s share price has bounced around as investors weigh its steady 1 year revenue and net income growth against concerns about valuation and slower device demand. The 1 month share price return has... Dec 9, 2025 - $BDX
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple